Healthcare provider profile · identity verified

Julia A Bowlin, MD

Family Practice · GREENVILLE, OH · NPI 1295787067

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	264	78
Losartan Potassium	Losartan Potassium	214	54
Levothyroxine Sodium	Levothyroxine Sodium	195	57
Lisinopril	Lisinopril	158	42
Omeprazole	Omeprazole	149	31
Amlodipine Besylate	Amlodipine Besylate	133	42
Simvastatin	Simvastatin	131	40
Furosemide	Furosemide	118	36
Metoprolol Succinate	Metoprolol Succinate	117	34
Metformin Hcl	Metformin Hcl	114	31
Potassium Chloride	Potassium Chloride	73	16
Donepezil Hcl	Donepezil Hcl	65	14
Rosuvastatin Calcium	Rosuvastatin Calcium	60	19
Tamsulosin Hcl	Tamsulosin Hcl	60	suppressed
Sertraline Hcl	Sertraline Hcl	58	17
Alendronate Sodium	Alendronate Sodium	57	14
Gabapentin	Gabapentin	56	13
Pantoprazole Sodium	Pantoprazole Sodium	56	12
Metoprolol Tartrate	Metoprolol Tartrate	55	17
Glimepiride	Glimepiride	46	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	45	23
Citalopram Hbr	Citalopram Hydrobromide	44	suppressed
Allopurinol	Allopurinol	42	15
Hydrochlorothiazide	Hydrochlorothiazide	40	suppressed
Famotidine	Famotidine	39	11
Synthroid	Levothyroxine Sodium	39	12
Fluticasone Propionate	Fluticasone Propionate	37	13
Januvia	Sitagliptin Phosphate	37	suppressed
Memantine Hcl	Memantine Hcl	37	suppressed
Trazodone Hcl	Trazodone Hcl	36	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	34	suppressed
Eliquis	Apixaban	33	suppressed
Jardiance	Empagliflozin	31	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	30	suppressed
Lovastatin	Lovastatin	29	suppressed
Celecoxib	Celecoxib	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	27	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Ozempic	Semaglutide	27	suppressed
Buspirone Hcl	Buspirone Hcl	25	suppressed
Latanoprost	Latanoprost	25	suppressed
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Propranolol Hcl	Propranolol Hcl	22	suppressed
Atenolol	Atenolol	21	suppressed
Carvedilol	Carvedilol	20	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Trulicity	Dulaglutide	20	suppressed
Nabumetone	Nabumetone	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Fenofibrate	Fenofibrate,micronized	18	suppressed
Pregabalin	Pregabalin	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Montelukast Sodium	Montelukast Sodium	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Raloxifene Hcl	Raloxifene Hcl	16	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Diltiazem Hcl	Diltiazem Hcl	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Methotrexate	Methotrexate Sodium	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Acebutolol Hcl	Acebutolol Hcl	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Cilostazol	Cilostazol	12	suppressed
Digoxin	Digoxin	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Divalproex Sodium Er	Divalproex Sodium	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Estradiol	Estradiol	11	suppressed
Metformin Hcl Er	Metformin Hcl	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Tramadol Hcl	Tramadol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error